AbbVie Inc. (ABBV)

AbbVie is outperforming expectations with strong commercial results, pipeline progress, and the legal win that secured Rinvoq's long-term market exclusivity. ABBV has raised the full-year revenue guid...

In the closing of the recent trading day, AbbVie (ABBV) stood at $236.56, denoting a -3.2% move from the preceding trading day.

AbbVie stock (NYSE: ABBV) rallied 11% in a week, largely driven by a key development that boosted the entire sector: Pfizer's agreement to lower its drug prices for Medicaid and a White House decision...

Stocks in the S&P 500 (^GSPC 0.41%) offer a miserly yield of 1.2% (on average) today. You can do way better than that and still invest in very attractive businesses.

ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

AbbVie said on Monday it would launch its ovarian cancer drug Elahere in the U.K. at a list price equal to that in the U.S.

Here's a statistic that should reshape how you think about investing: Companies that consistently raise dividends have crushed the S&P 500 by 2.5 percentage points annually since 1972. Not tech highfl...

AbbVie is rated a strong buy for its strong dividend growth, robust fundamentals, and proven track record as a Dividend King. ABBV offers a compelling mix of a 3% yield and nearly 7% annual historical...